InvestorsHub Logo
Followers 25
Posts 1513
Boards Moderated 0
Alias Born 12/14/2006

Re: midastouch017 post# 3678

Wednesday, 12/18/2013 6:43:42 AM

Wednesday, December 18, 2013 6:43:42 AM

Post# of 44784
"I think a major paradigm shift is going to be led by those companies that have good balance sheets, although there are very few of those currently in this space. It will also be led by companies that have partners with viable business models. Pluristem has a great partner in United Therapeutics Corp. (UTHR:NASDAQ). Mesoblast has Teva. Athersys has Pfizer. And in all cases, the business models of cells in a bottle, like pills in a bottle, are going to look attractive to big pharma."...

http://jutiagroup.com/20131217-the-new-year-heralds-a-transition-in-stem-cell-development-jason-kolbert/

Disclaimer: Information is offered for discussion purposes only and is not guaranteed to be complete, unbiased, current or accurate and is subject to change without notice and is not be relied upon to make any investment decisions.